About
Memic Hominis is a next-generation robotic surgical system developed by Memic Medtech, built around a bioinspired design that replicates the full range of motion of the human arm — shoulder, elbow, and wrist articulation — at a miniaturized scale inside the patient's body. The system is FDA-cleared for benign gynecological procedures including total hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal, all performed via a transvaginal natural orifice approach that leaves no external scars. The Hominis platform translates the surgeon's precise hand movements into micro-scale robotic articulation, delivering 360-degree dexterity in confined anatomical spaces that traditional laparoscopic or robotic tools cannot easily reach. Its compact system design integrates smoothly into standard operating rooms without requiring specialized infrastructure, reducing total cost of care compared to legacy robotic platforms. The system is intended for trained surgeons operating in hospital or surgical center environments and is backed by a growing body of clinical evidence supporting its safety and efficacy. With an emphasis on workflow efficiency, reduced patient recovery time, and lower procedural cost, Memic Hominis represents a significant advancement for minimally invasive gynecological surgery. It is particularly suited for health systems seeking a cost-effective robotic surgery option without compromising surgical capability.
Key Features
- Bioinspired Robotic Arms: Miniaturized arms that replicate the full range of human shoulder, elbow, and wrist motion, delivering unprecedented dexterity inside the patient's body.
- Transvaginal Natural Orifice Approach: Enables scarless surgery by accessing the operative site through a natural orifice, eliminating external abdominal incisions and reducing patient recovery time.
- 360-Degree Articulation: Provides surgeons with full rotational control and reach in confined anatomical spaces, surpassing the limitations of conventional laparoscopic and robotic tools.
- Compact, OR-Ready Footprint: Designed to integrate into standard operating rooms without specialized infrastructure, minimizing capital and operational costs for healthcare facilities.
- FDA-Cleared for Benign Gynecological Procedures: Cleared for hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal in adult patients under trained physician supervision.
Use Cases
- Hospitals and surgical centers seeking a cost-effective robotic platform for benign gynecological surgery without the high capital cost of legacy systems.
- Gynecological surgeons performing hysterectomies who want to offer patients a scarless, natural orifice procedure with shorter recovery times.
- Health systems looking to expand their minimally invasive robotic surgery program into outpatient or ambulatory surgical center settings.
- Surgical training programs integrating next-generation bioinspired robotic platforms into gynecological surgery curricula.
- OR administrators aiming to reduce setup complexity and room turnover time by adopting a compact, streamlined robotic system.
Pros
- Scarless Patient Outcomes: The transvaginal approach eliminates external incisions, resulting in faster recovery, less post-operative pain, and improved cosmetic outcomes for patients.
- Cost-Effective Robotic Surgery: More affordable than legacy large-footprint robotic systems, making advanced robotic surgery accessible to a broader range of hospitals and surgical centers.
- Human-Level Dexterity at Micro Scale: Bioinspired arm design translates natural surgeon movement into precise robotic articulation, reducing fatigue and improving procedural accuracy.
- Streamlined OR Integration: Compact design and intuitive workflow reduce setup time and fit seamlessly into existing operating room environments.
Cons
- Limited Procedural Scope: Currently cleared only for benign gynecological procedures; not indicated for oncological or general surgery applications at this time.
- Requires Specialized Surgeon Training: Surgeons must complete dedicated training on the Hominis system before clinical use, adding onboarding time and cost for institutions.
- Enterprise/Hospital-Only Availability: The system is a capital medical device sold to healthcare institutions, not accessible as a software subscription or individual tool.
Frequently Asked Questions
What procedures is Memic Hominis cleared to perform?
Memic Hominis is FDA-cleared for adult benign gynecological procedures including total hysterectomy (with or without salpingo-oophorectomy or salpingectomy), salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal via a transvaginal laparoscopic-assisted approach.
How does Memic Hominis differ from traditional robotic surgery systems?
Unlike large multi-arm robotic platforms, Memic Hominis uses bioinspired miniaturized arms that mimic human anatomy, enabling a transvaginal natural orifice approach with no external abdominal incisions, a smaller OR footprint, and lower overall cost of care.
Is the Memic Hominis system suitable for cancer treatment?
No. The safety and effectiveness of the Memic Hominis system have been established only for benign gynecological procedures. It is not indicated for oncological procedures, and outcomes related to cancer treatment have not been evaluated.
What training is required to use the Memic Hominis system?
The system must be operated by trained physicians in an operating room environment. Memic Medtech provides dedicated training programs (Momentis University equivalent) to certify surgeons on proper use of the platform.
How does the transvaginal approach benefit patients?
By accessing the surgical site through a natural orifice rather than external abdominal incisions, patients experience no visible scarring, reduced post-operative pain, lower risk of wound complications, and typically faster recovery times compared to traditional laparoscopic or open surgery.
